Neumora Therapeutics, a clinical-stage biopharmaceutical company, is working to revolutionize the treatment of brain diseases with targeted therapies, offering hope to patients and families affected by these conditions.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering innovative treatments for brain diseases, with a promising pipeline and significant investor confidence.

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company making significant strides in developing innovative treatments for brain diseases, with its lead candidate NMRA-861 showing promise in treating schizophrenia and other neuropsyc…

Neumora Therapeutics reported a net loss of $68 million in Q1 2025, but remains committed to developing targeted therapies for brain diseases despite financial challenges.